Please ensure Javascript is enabled for purposes of website accessibility

Down 41%: Is Sarepta Therapeutics Worth the Risk?

By George Budwell - Apr 21, 2016 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA's latest briefing on eteplirsen doesn't bode well for the drug's chances of approval this year.

Source: Pixabay 

What: In what's turned into a recurring theme, shares of the clinical-stage biotech Sarepta Therapeutics (SRPT 2.76%) are getting hammered yet again on negative regulatory news for eteplirsen, its experimental Duchenne muscular dystrophy (DMD) drug.

Specifically, the biotech's shares fell by as much as 41% in early trading Thursday after the FDA released its updated briefing documents ahead of eteplirsen's scheduled advisory committee meeting next Monday.

Despite Sarepta's attempts to bolster eteplirsen's regulatory application by submitting additional data, the agency apparently hasn't changed its negative view of the drug's clinical profile, based on this latest internal review. 

So what: Sarepta's shares had been on the rebound heading into this advisory committee meeting due to the renewed optimism among bulls that eteplirsen would somehow garner a conditional approval this year. In particular, the optimists seemed to think that the additional data -- combined with the overwhelmingly strong support from many patients who participated in eteplirsen's mid-stage trial -- would be enough to get the drug over the hump, so to speak. The FDA, though, clearly has different ideas, even reaffirming its earlier statement that eteplirsen's mid-stage trial was so small that "a single patient could change the results substantially."

Now what: Sarepta and the FDA will go toe-to-toe next Monday over their varying interpretations of eteplirsen's clinical results. Unfortunately, Sarepta's argument for a conditional approval seems to be coming apart at the seams. The overarching problem is that eteplirsen's mid-stage trial -- which is being used as the basis for this regulatory filing --  is simply too small to enable a robust statistical analysis. So, I think investors need to prepare themselves for the high probability that the FDA will  reject eteplirsen's regulatory application, in spite of the documented need for new DMD treatments.

Looking ahead, I think the agency is going to recommend that Sarepta complete its ongoing pivotal-stage trial before refiling. The bad news is that the trial won't wrap up until 2019, meaning that Sarepta could be several years away from finally transforming into a commercial operation. As such, Sarepta's steep risk profile looks to me like it greatly outweighs its upside potential right now.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$71.13 (2.76%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.